The FDA has accepted for review the sBLA for subcutaneous lecanemab-irmb as a weekly starting dose for Alzheimer disease.
As doctors learn why GLP-1s don't work for about 50% of people, they are also learning more about the complex drivers of ...
The combination of subcutaneous daratumumab with VRd was approved in July 2024 for induction and consolidation in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results